Physician profile
Marcjonathan Serota
NPI 1740410463
$3,215,941.92
in general payments reported to CMS, 2019-2025
34 companies · $432K in 2025
The $432K reported for 2025 was more than what 99% of Dermatology providers received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $523K · 2020: $184K · 2021: $356K · 2022: $411K · 2023: $637K · 2024: $673K · 2025: $432K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $1.4M · Travel and Lodging: $184K · Consulting Fee: $149K · Food and Beverage: $30K · Honoraria: $13K · Education: $97.22.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $1,366,563.85 |
| Travel and Lodging | $183,623.82 |
| Consulting Fee | $148,538.00 |
| Food and Beverage | $30,255.03 |
| Honoraria | $12,800.00 |
| Education | $97.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $759,567.12 | 2019-2025 | |
| Regeneron Healthcare Solutions, INC. | $711,483.06 | 2019-2025 | Dupixent |
| E.R. Squibb & Sons, L.L.C. | $285,229.73 | 2021-2025 | Sotyktu |
| Ucb, INC. | $273,775.41 | 2019-2025 | Bimzelx, Cimzia |
| Incyte Corporation | $249,370.88 | 2021-2025 | Opzelura, Opzelura |
| Amgen INC. | $177,344.51 | 2020-2025 | Otezla, Otezla, Enbrel |
| Novartis Pharmaceuticals Corporation | $163,612.94 | 2019-2025 | |
| Lilly USA, LLC | $131,384.14 | 2019-2025 | Ebglyss |
| Pfizer INC. | $99,856.92 | 2019-2025 | |
| Arcutis Biotherapeutics, INC. | $97,652.09 | 2023-2025 | Zoryve |
| Celgene Corporation | $88,967.55 | 2019 | |
| Genentech USA, INC. | $62,588.76 | 2019-2023 | Xolair |
| Dermavant Sciences, INC. | $44,669.32 | 2022-2024 | Vtama |
| Galderma Laboratories, L.P. | $34,305.59 | 2019-2025 | Nemluvio |
| Organon LLC | $12,903.86 | 2025 | Vtama |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Eli Lilly and Company | $7,897.93 | 2025 | Ebglyss |
| Vyne Pharmaceuticals INC. | $7,454.53 | 2020-2021 | |
| Leo Pharma INC. | $3,212.82 | 2021-2022 | |
| Abbvie INC. | $1,873.15 | 2019-2025 | Rinvoq, Skyrizi |
| Kowa Pharmaceuticals America, INC. | $650.00 | 2025 | Zoryve |
| Allergan, INC. | $600.00 | 2019 | |
| Sun Pharmaceutical Industries INC. | $585.81 | 2019-2023 | Ilumya |
| Sanofi-Aventis U.S. LLC | $367.28 | 2019-2021 | |
| Janssen Biotech, INC. | $173.01 | 2019-2024 | Tremfya |
| Alk-Abello, INC | $71.45 | 2020 | |
| Dermira, INC. | $65.56 | 2019-2020 | |
| Epi Health, LLC | $53.45 | 2019-2021 | |
| Helsinn Therapeutics (U.S.), INC. | $45.13 | 2020-2021 | |
| Journey Medical Corporation | $40.60 | 2019-2022 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $40.55 | 2021-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $29.01 | 2023 | Spevigo |
| Mallinckrodt Hospital Products INC. | $28.50 | 2025 | Acthar |
| Avion Pharmaceuticals | $24.25 | 2023 | Balcoltra |
| Dusa Pharmaceuticals, INC. | $17.01 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Marcjonathan Serota listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.